While the risk of complications seems to be associated with anti-TNF drug levels and IBD patients with active disease seem to have increased clearance of anti-TNF levels, our approach might potentially lead to a misclassification of exposure when defining the last use alone [19, 42, 43]. Here, TNF is linked to inflammatory bowel disease.